Critical Care & Emergencies (all articles)
New studies show reduced prevalence and severity of SARS-CoV-2 infection in ABO blood group O
18 Oct, 2020 | 23:16h | UTCStudy 1: Reduced prevalence of SARS-CoV-2 infection in ABO blood group O – Blood Advances
Commentaries: People with blood type O may have lower risk of Covid-19 infection and severe illness, two new studies suggest – CNN AND Studies offer new evidence for possible link between blood type and COVID-19 susceptibility – American Society of Hematology
Acute Respiratory Distress Syndrome: Contemporary management and novel approaches during COVID-19
18 Oct, 2020 | 23:11h | UTCSource: Grupo UTI Clínica HCFMUSP
Commentary on Twitter
Review article in @_Anesthesiology showing a summary of 25 yr of ARDS intervention trials and contemporary management and novel approaches during COVID-19 ✅#ICU #CriticalCare #COVID__19 #ARDS https://t.co/MjLGgoTGy6 pic.twitter.com/wkVoOikhKQ
— Alice Blet, MD, PhD 🩺🔬 (@BletAlice) October 9, 2020
Cytokine elevation in severe and critical COVID-19: A rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes
18 Oct, 2020 | 23:07h | UTC
Commentary on Twitter
The cytokine storm of severe #COVID19 and how it differs from ARDS, sepsis, and CAR-T cytokine release syndrome. Best review to date on this ★
Today @LancetRespirMed https://t.co/BOUjvIOWLi @danleisman @Poietic_Justice @IcahnMountSinai @CDMD62
🙏 for pulling all this together pic.twitter.com/qZCPbrxvYU— Eric Topol (@EricTopol) October 16, 2020
SCCM International consensus conference on prediction and identification of long-term impairments after critical illness
18 Oct, 2020 | 22:59h | UTCSystematic review: Prediction Models for Physical, Cognitive, and Mental Health Impairments After Critical Illness: A Systematic Review and Critical Appraisal – Critical Care Medicine
Source: Grupo UTI Clínica HCFMUSP
Commentary on Twitter
https://twitter.com/Michael_Harhay/status/1316728913368952834
Guideline: Management and prevention of anemia (acute bleeding excluded) in adult critical care patients
18 Oct, 2020 | 22:52h | UTC
Commentary on Twitter
Latest guidelines for anemia 🩸in critically ill patients by @SigLasocki published in @AccpmJ
📈 what threshold?
🩸 how many RBCs?
💉EPO as a substitute?➡️check the Full 📃 for the answers !https://t.co/sJIIbunwKB#CriticalCare #ICU #Anemia #MedTwitter #AnesthTwitter https://t.co/AMD5xZnWDr
— Alice Blet, MD, PhD 🩺🔬 (@BletAlice) October 15, 2020
[Preprint] WHO SOLIDARITY trial results published; Remdesivir, Hydroxychloroquine, Lopinavir, and Interferon do not improve outcomes in Covid-19
16 Oct, 2020 | 09:42h | UTCRepurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results – medRxiv
Commentary: Remdesivir and interferon fall flat in WHO’s megastudy of COVID-19 treatments – Science
Commentaries on Twitter
Results of the @WHO SOLIDARITY trial:
4 drugs tested in 11,266 patients with COVID in 405 hospitals in 30 countries:
– hydroxychloroquine
– lopinavir
– remdesevir
– interferonNo clear benefit of any of them on survival. https://t.co/ohtTAFaSnc pic.twitter.com/2fO9E8zs8h
— Martin Landray (@MartinLandray) October 16, 2020
This is blockbuster from @WHO: 'Remdesivir, Hydroxychloroquine, Lopinavir and Interferon regimens have little or no effect on hospitalized COVID-19, as indicated by mortality, initiation of ventilation and duration of hospital stay. @medrxivpreprint https://t.co/aNGLzLL5uW pic.twitter.com/daOAMVW62u
— Harlan Krumholz (@hmkyale) October 15, 2020
Viewpoint: Sensible medicine—balancing intervention and inaction during the COVID-19 pandemic
16 Oct, 2020 | 09:38h | UTCSensible Medicine—Balancing Intervention and Inaction During the COVID-19 Pandemic – JAMA
Author interview: Sensible Medicine—Balancing Intervention and Inaction During the COVID-19 Pandemic
Commentary on Twitter
https://twitter.com/seymoc/status/1316765788523511809
Cochrane living systematic review: Not enough evidence to recommend convalescent plasma for people with COVID‐19
16 Oct, 2020 | 09:34h | UTC
Commentary on Twitter
Just updated: @CochraneCollab living review investigates the use of convalescent plasma to treat people with COVID-19: https://t.co/Or5qmxki8H “We remain very uncertain about the effectiveness & safety of using convalescent plasma for people with #COVID19".
— The Cochrane Library (@CochraneLibrary) October 13, 2020
Study: Negative D-dimer safely rules out DVT as a stand-alone test
16 Oct, 2020 | 09:26h | UTCNegative D-dimer safely ruled out DVT as a stand-alone test – Blood Advances
Phase 3 trials show positive results for cefiderocol, but questions remain
15 Oct, 2020 | 09:07h | UTCPhase 3 trials show positive results for cefiderocol, but questions remain – CIDRAP
Podcast: Ten things every new doctor should know about drug reactions
15 Oct, 2020 | 09:02h | UTCTen Things Every New Doctor Should Know About Drug Reactions – JAMA
Genomic evidence for reinfection with SARS-CoV-2: A case study
14 Oct, 2020 | 09:39h | UTCGenomic evidence for reinfection with SARS-CoV-2: a case study – The Lancet Infectious Diseases
Commentaries: First Case Of COVID-19 Reinfection In The US Confirmed; Exposure to Virus May Not Guarantee Protective Immunity, Says New Lancet Study – Health Policy Watch AND What reinfections mean for COVID-19 – The Lancet Infectious Diseases AND You can get reinfected with Covid-19 but still have immunity. Let’s explain. – Vox AND A 25-Year-Old Nevada Man Got COVID-19 Twice. Here’s What We Know—and Don’t Know—About Reinfection – TIME
Related: Dutch woman dies after catching Covid-19 twice, the first reported reinfection death – CNN
Updated NIH COVID-19 Treatment Guidelines
14 Oct, 2020 | 09:41h | UTCCoronavirus Disease 2019 (COVID-19) Treatment Guidelines – National Institutes of Health
See also: What’s New in the Guidelines
Non-respiratory presentations of COVID-19, a clinical review
14 Oct, 2020 | 09:33h | UTC
Monoclonal antibody trial halted for safety concern
14 Oct, 2020 | 09:30h | UTCMonoclonal Antibody Trial Halted for Safety Concern – Brief19
Review: Coagulopathy, venous thromboembolism, and anticoagulation in patients with COVID‐19
13 Oct, 2020 | 01:12h | UTC
[Preprint] Exclusion of bacterial co-infection in COVID-19 using baseline inflammatory markers and their response to antibiotics
13 Oct, 2020 | 01:08h | UTC
Commentary on Twitter
Anyone think we prescribe too many #antibiotics in #COVID19?
Looking for ways to prescribe less?
Well, our latest *PREPRINT* (not peer reviewed!) may be of interest. #antibioticstewardship https://t.co/qUimnZhwg7 Thread (1/7) pic.twitter.com/Z6gaGMgduv— Gabriele Pollara (@gpollara) October 12, 2020
Meta-analysis: ECMO for severe ARDS
13 Oct, 2020 | 00:58h | UTC
Commentary on Twitter
#ECMO vs conventional strategies in severe #ARDS, meta-analysis of individual patient data:#ECMO-group pts spent more days alive out of the #ICU & without respiratory, cardiovascular, renal, neurological failure. Open access @yourICM #FOAMcc #FOAMecmo https://t.co/3PV2gAHA3G https://t.co/k6MQYUjKgu
— Intensive Care Medicine (@yourICM) October 7, 2020
Review: Characteristics of SARS-CoV-2 and COVID-19
12 Oct, 2020 | 00:49h | UTCCharacteristics of SARS-CoV-2 and COVID-19 – Nature Reviews Microbiology
Commentary on Twitter
Characteristics of SARS-CoV-2 and COVID-19
Zheng-Li Shi et al. summarize the exceptional amount of research that has characterized SARS-CoV-2 and COVID-19, discussing the emergence and virology of SARS-CoV-2 and the pathogenesis and treatment of COVID-19https://t.co/kGL6nOdOYu pic.twitter.com/1ePqHvLxFz
— Nature Reviews Microbiology (@NatureRevMicro) October 6, 2020
Trends in clinical profiles, organ support use and outcomes of patients with cancer requiring unplanned ICU admission: a multicenter cohort study
12 Oct, 2020 | 00:31h | UTC
Commentary on Twitter
Read @f_g_zampieri et al: #ICU: a place for complex #oncology patients? outcomes of critically ills w cancer improved in past 8y
> 30% bed/days use
reduced mortality/ICU LOS
-> improved overall care?
Open #FOAMcc on @yourICM at https://t.co/lUKQsZvLcR#CCCF2020 @Dr_Cit https://t.co/8R8lDKEZal pic.twitter.com/VJ5XZLoVrA— Intensive Care Medicine (@yourICM) October 7, 2020
Prevalence, associated factors and outcomes of pressure injuries in adult intensive care unit patients: the DecubICUs study
12 Oct, 2020 | 00:34h | UTC
Commentary on Twitter
DecubICUs study results: pressure injuries common in adult #ICU: 59.2% ICU-acquired, prevalence 16.2%.
Optimal care standards, increased awareness, proper resource allocation, focused research pivotal to tackle this main #ptsafety threat @StijnBLOT @ESICM https://t.co/gfJ9x06dnB pic.twitter.com/bUeOVwoVxk— Intensive Care Medicine (@yourICM) October 9, 2020
Esophageal emergencies: Another important cause of acute chest pain
12 Oct, 2020 | 00:30h | UTCEsophageal emergencies: another important cause of acute chest pain – Insights into Imaging
RECOVERY trial: Effect of hydroxychloroquine in hospitalized patients with Covid-19
9 Oct, 2020 | 09:15h | UTC
Less is more: Critically ill status is not a carte blanche for unlimited antibiotic use
12 Oct, 2020 | 00:32h | UTC
Remdesivir for the treatment of Covid-19 — final report
9 Oct, 2020 | 09:13h | UTCRemdesivir for the Treatment of Covid-19 — Final Report – New England Journal of Medicine
Commentary: BREAKING NEWS: Final remdesivir results published after 139 days of waiting – Brief19
Commentary on Twitter
📍Remdesivir trial (ACTT-1) final results finally out.
📍Still no mortality benefit. A study with tons of patients could show some small mortality benefit.
📍Those who recover, do so a bit faster.
📍Not the game-changer that was hyped.via @Brief_19https://t.co/jWRJypJIuS
— Jeremy Faust MD MS (ER physician) (@jeremyfaust) October 8, 2020